Samsca

Otsuka has launched Samsca (tolvaptan) for the treatment of hyponatraemia secondary to SIADH.

Tolvaptan is a selective vasopressin V2-receptor antagonist that binds to the receptor with a greater affinity than the arginine vasopressin found in the body. This causes an increase in urine excretion resulting in increased aquaresis, decreased urine osmolarity and increased serum sodium levels.

Care should be taken in patients with diabetes mellitus, urinary outflow obstruction and those at risk of demyelinisation syndromes. Fluid and electrolyte status should be closely monitored.

View Samsca drug record

Further information: Otsuka

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in